Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study

ABSTRACT: BACKGROUND: Lanthanum carbonate (FOSRENOL(®)) is an effective, well-tolerated phosphate binder. The ability of lanthanum to reduce serum phosphorus levels to ≤5.5 mg/dL in patients with end-stage renal disease (ESRD) was assessed in a clinical practice setting. METHODS: A 16-week, phase IV...

Descripción completa

Detalles Bibliográficos
Autores principales: Vemuri, Nirupama, Michelis, Michael F, Matalon, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197476/
https://www.ncbi.nlm.nih.gov/pubmed/21962172
http://dx.doi.org/10.1186/1471-2369-12-49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197476/
https://www.ncbi.nlm.nih.gov/pubmed/21962172
http://dx.doi.org/10.1186/1471-2369-12-49

Ejemplares similares